Category: Antonio Magnelli

  • Investing in biologics excellence

    In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs. Yet, despite the immense potential of the field, biologics have remained largely untapped. Now, amid a wave of innovation, investors and drugmakers are putting their weight behind the drug class. “Biologics have revolutionised treatments for several serious […]